FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease - FDA Press Releases

FDA approves new drug for treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR). This is the first FDA-approved treatment for this rare, debilitating and often fatal genetic disease and the first FDA approval of a new class of drugs called small interfering ribonucleic acid (siRNA) treatment.

from Food and Drug Administration--Press Releases https://ift.tt/2KIKNyL
via IFTTT